Literature DB >> 10379876

Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases.

R Taetle1, M Aickin, J M Yang, L Panda, J Emerson, D Roe, L Adair, F Thompson, Y Liu, L Wisner, J R Davis, J Trent, D S Alberts.   

Abstract

Cytogenetics provides important insights into the molecular pathogenesis of human cancers. Although extensive data exist on recurring cytogenetic abnormalities in hematologic cancers, data on individual solid tumor types remain limited. Previous studies of ovarian carcinoma indicated the presence of multiple, complex clonal chromosome abnormalities. Cytogenetics remains one of a few techniques capable of detecting these multiple, simultaneously occurring genetic abnormalities. We describe cytogenetic abnormalities from a series of 244 primary ovarian cancer specimens referred to a single institution. A total of 201/244 cases had fully characterized clonal chromosome abnormalities, of which 134 showed clonal chromosome breakpoints. We used a novel statistical technique to detect nonrandom chromosome breakpoints at the level of chromosome regions. Nonrandom occurrence of chromosome breakpoints was detected at regions 1p1*, 1q1*, 1p2*, 1q2*, 1p3*, 1q3, 3p1*, 1q4*, 6q1*, 6p2, 6q2, 7p1*, 7q1, 7p2*, 11p1*, 11q1, 11q2*, 12p1, 12q2*, 13p1, and 19q1. Simultaneous occurrence of multiple abnormalities was common. However, 120/134 cases had breakpoints at one or more of 13 commonly involved regions (*), suggesting a hierarchy of genetic abnormalities. Among clinical and tumor variables that predict patient survival, tumor grade was significantly associated with the presence of chromosome breakpoints. In additional studies, we show that nonrandom chromosome abnormalities are associated with impaired survival in ovarian cancer and that specific, nonrandomly involved chromosome regions retain significant effects on survival when analyses are controlled for important clinical variables. Additional specific chromosome abnormalities in this series are described, including chromosome gains and losses in near-diploid cases and homogeneously staining regions. These results suggest that recurring, nonrandom chromosome abnormalities are important in the pathogenesis and/or progression of ovarian cancers, and target areas of the genome for molecular genetic studies.

Entities:  

Mesh:

Year:  1999        PMID: 10379876

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  17 in total

Review 1.  Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

Authors:  Analisa DiFeo; Goutham Narla; John A Martignetti
Journal:  Mt Sinai J Med       Date:  2009-12

2.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

3.  High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer.

Authors:  Marcus Bernardini; Chung-Hae Lee; Ben Beheshti; Mona Prasad; Monique Albert; Paula Marrano; Heather Begley; Patricia Shaw; Al Covens; Joan Murphy; Barry Rosen; Salomon Minkin; Jeremy A Squire; Pascale F Macgregor
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

4.  Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer.

Authors:  Jane Bayani; Jana Paderova; Joan Murphy; Barry Rosen; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

5.  Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis.

Authors:  Manasa Ramakrishna; Louise H Williams; Samantha E Boyle; Jennifer L Bearfoot; Anita Sridhar; Terence P Speed; Kylie L Gorringe; Ian G Campbell
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

6.  Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas.

Authors:  Christine S Walsh; Seishi Ogawa; Daniel R Scoles; Carl W Miller; Norihiko Kawamata; Steven A Narod; H Phillip Koeffler; Beth Y Karlan
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 7.  Large-scale genomic analysis of ovarian carcinomas.

Authors:  Kylie L Gorringe; Ian G Campbell
Journal:  Mol Oncol       Date:  2008-12-24       Impact factor: 6.603

8.  Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.

Authors:  Jane Bayani; Miltiadis Paliouras; Chris Planque; Shannon J C Shan; Cassandra Graham; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2008-07-22       Impact factor: 6.603

9.  Differential roles of telomere attrition in type I and II endometrial carcinogenesis.

Authors:  Esra A Akbay; Cristina M Contreras; Samanthi A Perera; James P Sullivan; Russell R Broaddus; John O Schorge; Raheela Ashfaq; Hossein Saboorian; Kwok-Kin Wong; Diego H Castrillon
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

10.  Protease inhibitor SERPINA1 expression in epithelial ovarian cancer.

Authors:  Karine Normandin; Benjamin Péant; Cécile Le Page; Manon de Ladurantaye; Véronique Ouellet; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Clin Exp Metastasis       Date:  2010-01-05       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.